Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
 
Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
  
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530 
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531 
   English Wikipedia
  Nephropedia Template TP (
  Twit Text
 
  DeepDyve Pubget Overpricing |    
 
  lüll Role of folate antagonists in the treatment of methicillin-resistant  Staphylococcus aureus infection Proctor RAClin Infect Dis  2008[Feb]; 46 (4): 584-93Methicillin-resistant Staphylococcus aureus (MRSA) infection has reached epidemic  proportions, and therapeutic options are limited because these strains are often  multidrug resistant. However, the new strains of community-acquired MRSA show  decreased resistance to trimethoprim-sulfamethoxazole. Clinical and experimental  reports show a mixture of successes and failures with  trimethoprim-sulfamethoxazole treatment. A reason for failure might be the amount  of thymidine released from damaged host tissues and bacteria, a concept  strengthened by the fact that S. aureus thermonuclease releases thymidine from  DNA. Thus, success or failure with trimethoprim-sulfamethoxazole may well depend  on the amount of tissue damage and organism burden, rather than acquisition of a  resistance gene. Clinical trials and experimental animal studies show high  failure rates, perhaps because of released thymidine. The use of  trimethoprim-sulfamethoxazole for community-acquired MRSA infection should not be  endorsed without further research.|*Methicillin Resistance[MESH]|Animals[MESH]|Anti-Infective Agents/pharmacology/*therapeutic use[MESH]|Community-Acquired Infections/drug therapy/microbiology[MESH]|Humans[MESH]|Staphylococcal Infections/*drug therapy/*microbiology[MESH]|Staphylococcus aureus/*drug effects[MESH]|Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology/*therapeutic use[MESH] |